Q-omics provides the consensus-scored WT1 profile across patient tissues and cancer cell-line models. WT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WT1 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, WT1 RNA expression shows 13,620 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, KIRP, and UCEC as cancer lineages where WT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WT1 survival associations across molecular data types. WT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WT1 RNA expression–survival associations across cancer types. High WT1 expression shows unfavorable associations in ACC, KIRC, BLCA, LGG and THCA, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WT1 RNA expression.
This table summarizes WT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for WT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WT1 shows lower tumor expression in KIRP, KICH, KIRC and UCEC and higher tumor expression in COAD and HNSC. The KIRP box plot shows higher WT1 RNA expression in normal versus tumor tissue (log2 FC = −3.317, t-test p < 0.001).
This table shows molecular features associated with WT1 in patient tissues and cancer cell lines. In patient samples, WT1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, WT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
